SCHEMBL1763068

SCHEMBL1763068

Cc1cc(C)c(S(=O)(=O)n2ccnn2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 7/20 0.45
NPSR1 Q6W5P4 2/20 0.44
MAPK1 P28482 1/20 0.43
MAPT P10636 3/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 1/20 0.41
PIK3CD O00329 1/20 0.40
PIK3CA P42336 1/20 0.40
PIK3CB P42338 1/20 0.40
PIK3CG P48736 1/20 0.40
ALDH1A1 P00352 4/20 0.39
POLB P06746 1/20 0.39
PKM P14618 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5694221 0.76 RAPGEF4 (0.45) RAPGEF4NPSR1MAPK1MAPTHTT
SCHEMBL1976805 0.74 CA1 (0.50) RAPGEF4NPSR1MAPTHTTGAA
SCHEMBL5396539 0.72 GRM4 (0.44) MAPTGAAALDH1A1MMP2MEN1
SCHEMBL9498378 0.71 FABP4 (0.57) TDP1GAAPIK3CDPIK3CAPIK3CB
SCHEMBL10587124 0.70 TSHR (0.48) MAPTGAAALDH1A1POLBPKM
SCHEMBL2386706 0.69 RAPGEF4 (0.45) RAPGEF4NPSR1MAPK1MAPTHTT
SCHEMBL841998 0.69 TSHR (0.58) RAPGEF4NPSR1MAPK1HTTMEN1
SCHEMBL9705778 0.67 ALDH1A1 (0.39) RAPGEF4MAPK1GAAALDH1A1POLB
SCHEMBL4947198 0.66
SCHEMBL1763261 0.66 ALDH1A1 (0.49) RAPGEF4NPSR1MAPK1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9567364-B2 Nucleotide and/or oligonucleotide and preparation process thereof Suzhou Ribo Life Sciene Co., Ltd. (CN) 2017-02-14 US claimed
EP-2599784-B1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF SUZHOU RIBO LIFE SCIENCE CO LTD (CN) 2016-06-29 EP claimed
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 US claimed
EP-2599784-A1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF Suzhou Ribo Life Science Co., Ltd (CN) 2013-06-05 EP claimed
US-20130123482-A1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) 2013-05-16 US claimed
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-05-19 US claimed
EP-0611999-B1 Reusable positive-charging organic photoconductor containing phthalocyanine pigment and cross-linking binder HEWLETT PACKARD CO (US) 1999-04-14 EP claimed
JP-57088196-A None JP disclosed
US-9567364-B2 Nucleotide and/or oligonucleotide and preparation process thereof Suzhou Ribo Life Sciene Co., Ltd. (CN) 2017-02-14 US disclosed
EP-2599784-B1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF SUZHOU RIBO LIFE SCIENCE CO LTD (CN) 2016-06-29 EP disclosed
US-8614312-B2 Method for preparing nucleotides and related analogues by synthesis on soluble substrate, and biological tools thus prepared CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-24 US disclosed
EP-2599784-A1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF Suzhou Ribo Life Science Co., Ltd (CN) 2013-06-05 EP disclosed
US-20130123482-A1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) 2013-05-16 US disclosed
US-5807837-A ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL SANKYO COMPANY, LIMITED (JP) 1998-09-15 US disclosed
US-5674856-A TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS SANKYO COMPANY, LIMITED (JP) 1997-10-07 US disclosed
EP-0611075-B1 Modified oligodeoxyribonucleotides, their preparation and their therapeutic use SANKYO CO (JP) 1996-12-18 EP disclosed
EP-0611075-A1 Modified oligodeoxyribonucleotides, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1994-08-17 EP disclosed
EP-0331032-B1 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES TAIHO PHARMACEUTICAL CO., LTD. (JP) 1993-04-28 EP disclosed
US-5032680-A Antitumor KURARAY CO., LTD. (JP) 1991-07-16 US disclosed
JP-S5788196-A PRODUCTION OF OLIGONUCLEOTIDES EISAI CO LTD 1982-06-01 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123482-A1 NUCLEOTIDE AND/OR OLIGONUCLEOTIDE AND PREPARATION PROCESS THEREOF RNGTT, RNMT, NUDT1 RAPGEF4 3189/4885NPSR1 554/4885MAPK1 1037/4885
US-20110118454-A1 METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED PNP, NUDT1, DUT RAPGEF4 939/4885NPSR1 1621/4885MAPK1 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.